Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Uma Borate, Devin Absher, Harry P. Erba, Boris Pasche

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

In spite of recent advances in molecular diagnostic techniques and expanded indications for allogeneic hematopoietic stem cell transplantation, treatment of acute myeloid leukemia (AML) remains a major challenge. In the last decade, several recurrent genetic abnormalities and gene mutations with prognostic implications have been identified. This has led to improved informed treatment decisions. However, there has been limited change in the use of nonspecific cytotoxic chemotherapy and mortality rates continue to be unacceptably high, with 5 year overall survival rates of older AML patients at 30% or less. Whole-genome sequencing offers hope for greater diagnostic accuracy and is likely to lead to further characterization of disease subsets with differential outcome and response to treatment. The holy grail of personalized targeted therapy for the individual AML patient, while minimizing toxicity and prolonging survival, appears closer than ever.

Original languageEnglish (US)
Pages (from-to)1289-1297
Number of pages9
JournalExpert review of anticancer therapy
Volume12
Issue number10
DOIs
StatePublished - Oct 2012

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.'. Together they form a unique fingerprint.

  • Cite this